Boston Scientific Corp (BSX) Stock Analysis

BSX- NYSE (USA) Also traded in: Germany
Boston Scientific Corp

Currently 1/5

Business Predictability Rank: 1-Star
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies

$36.54

0.99(2.64%) Volume: 8,378,188 7:08PM EDT

Avg Vol (1m): 6,695,091

3 Medium Warning Signs 2 Good Signs

Market Cap : 50.53 B	Enterprise Value : 56.82 B	P/E (TTM) : 101.50	P/B : 6.52

RSS

Manual of Stocks™ Web APP

Manual of Stocks™

Sorry. Only PremiumPlus Member can access this feature.

Free Trial

Also traded in: Germany

Financial Strength : 5/10

		vs industry	vs history
Cash-to-Debt	0.03	BSX's Cash-to-Debt is ranked lower than 98% of the 330 Companies in the Global Medical Devices industry. ( Industry Median: 2.32 vs. BSX: 0.03 ) Ranked among companies with meaningful Cash-to-Debt only. =GURUF("BSX","Cash-to-Debt")	BSX' s Cash-to-Debt Range Over the Past 10 Years Min: 0.03 Med: 0.15 Max: 4.69 Current: 0.03 0.03 - 4.69 =GURUF("BSX","Cash-to-Debt")
Equity-to-Asset	0.40	BSX's Equity-to-Asset is ranked lower than 86% of the 309 Companies in the Global Medical Devices industry. ( Industry Median: 0.63 vs. BSX: 0.40 ) Ranked among companies with meaningful Equity-to-Asset only. =GURUF("BSX","Equity-to-Asset")	BSX' s Equity-to-Asset Range Over the Past 10 Years Min: 0.18 Med: 0.51 Max: 0.83 Current: 0.4 0.18 - 0.83 =GURUF("BSX","Equity-to-Asset")
Debt-to-Equity	0.84	BSX's Debt-to-Equity is ranked lower than 84% of the 220 Companies in the Global Medical Devices industry. ( Industry Median: 0.30 vs. BSX: 0.84 ) Ranked among companies with meaningful Debt-to-Equity only. =GURUF("BSX","Debt-to-Equity")	BSX' s Debt-to-Equity Range Over the Past 10 Years Min: 0.06 Med: 0.54 Max: 3.64 Current: 0.84 0.06 - 3.64 =GURUF("BSX","Debt-to-Equity")
Debt-to-EBITDA	3.24	BSX's Debt-to-EBITDA is ranked lower than 67% of the 158 Companies in the Global Medical Devices industry. ( Industry Median: 1.98 vs. BSX: 3.24 ) Ranked among companies with meaningful Debt-to-EBITDA only. =GURUF("BSX","Debt-to-EBITDA")	BSX' s Debt-to-EBITDA Range Over the Past 10 Years Min: -88.33 Med: 3.64 Max: 37.25 Current: 3.24 -88.33 - 37.25 =GURUF("BSX","Debt-to-EBITDA")
Interest Coverage	7.13	BSX's Interest Coverage is ranked lower than 82% of the 212 Companies in the Global Medical Devices industry. ( Industry Median: 66.37 vs. BSX: 7.13 ) Ranked among companies with meaningful Interest Coverage only. =GURUF("BSX","Interest Coverage")	BSX' s Interest Coverage Range Over the Past 10 Years Min: 2.47 Med: 3.51 Max: 6.69 Current: 7.13 2.47 - 6.69 =GURUF("BSX","Interest Coverage")

Piotroski F-Score: 7
Altman Z-Score: 2.68
Beneish M-Score: -2.44
WACC vs ROIC	8.69% 5.52% WACC ROIC

Profitability & Growth : 8/10

		vs industry	vs history
Operating Margin %	17.42	BSX's Operating Margin % is ranked higher than 78% of the 312 Companies in the Global Medical Devices industry. ( Industry Median: 1.96 vs. BSX: 17.42 ) Ranked among companies with meaningful Operating Margin % only. =GURUF("BSX","Operating Margin %")	BSX' s Operating Margin % Range Over the Past 10 Years Min: 12.22 Med: 13.1 Max: 16.92 Current: 17.42 12.22 - 16.92 =GURUF("BSX","Operating Margin %")
Net Margin %	5.48	BSX's Net Margin % is ranked higher than 50% of the 312 Companies in the Global Medical Devices industry. ( Industry Median: 1.40 vs. BSX: 5.48 ) Ranked among companies with meaningful Net Margin % only. =GURUF("BSX","Net Margin %")	BSX' s Net Margin % Range Over the Past 10 Years Min: -56.12 Med: -2.45 Max: 5.79 Current: 5.48 -56.12 - 5.79 =GURUF("BSX","Net Margin %")
ROE %	7.12	BSX's ROE % is ranked higher than 51% of the 304 Companies in the Global Medical Devices industry. ( Industry Median: 0.95 vs. BSX: 7.12 ) Ranked among companies with meaningful ROE % only. =GURUF("BSX","ROE %")	BSX' s ROE % Range Over the Past 10 Years Min: -44.65 Med: -2.79 Max: 5.32 Current: 7.12 -44.65 - 5.32 =GURUF("BSX","ROE %")
ROA %	2.75	BSX's ROA % is ranked higher than 52% of the 332 Companies in the Global Medical Devices industry. ( Industry Median: -0.26 vs. BSX: 2.75 ) Ranked among companies with meaningful ROA % only. =GURUF("BSX","ROA %")	BSX' s ROA % Range Over the Past 10 Years Min: -21.16 Med: -1.04 Max: 2.03 Current: 2.75 -21.16 - 2.03 =GURUF("BSX","ROA %")
ROC (Joel Greenblatt) %	79.06	BSX's ROC (Joel Greenblatt) % is ranked higher than 90% of the 327 Companies in the Global Medical Devices industry. ( Industry Median: 3.87 vs. BSX: 79.06 ) Ranked among companies with meaningful ROC (Joel Greenblatt) % only. =GURUF("BSX","ROC (Joel Greenblatt) %")	BSX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years Min: -144.7 Med: -14.88 Max: 69.85 Current: 79.06 -144.7 - 69.85 =GURUF("BSX","ROC (Joel Greenblatt) %")
3-Year Revenue Growth Rate	5.20	BSX's 3-Year Revenue Growth Rate is ranked higher than 52% of the 254 Companies in the Global Medical Devices industry. ( Industry Median: 4.30 vs. BSX: 5.20 ) Ranked among companies with meaningful 3-Year Revenue Growth Rate only. =GURUF("BSX","3-Year Revenue Growth Rate")	BSX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years Min: -10.5 Med: 4.9 Max: 29 Current: 5.2 -10.5 - 29 =GURUF("BSX","3-Year Revenue Growth Rate")
3-Year EBITDA Growth Rate	64.10	BSX's 3-Year EBITDA Growth Rate is ranked higher than 95% of the 232 Companies in the Global Medical Devices industry. ( Industry Median: 7.50 vs. BSX: 64.10 ) Ranked among companies with meaningful 3-Year EBITDA Growth Rate only. =GURUF("BSX","3-Year EBITDA Growth Rate")	BSX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years Min: 0 Med: 13.15 Max: 83.1 Current: 64.1 0 - 83.1 =GURUF("BSX","3-Year EBITDA Growth Rate")

GuruFocus has detected 3 Warning Signs with Boston Scientific Corp BSX.

More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.

» BSX's 30-Y Financials

Financials (Next Earnings Date: 2018-10-26)

Revenue & Net Income

Cash & Debt

Operating Cash Flow & Free Cash Flow

Operating Cash Flow & Net Income

» BSX's Warning Signs

Warning Signs

Subscribe to see Warning Signs. .

Start your free trial

» Details

Guru Trades

Q3 2017

Q4 2017

Q1 2018

Q2 2018

» Details

Insider Trades

Financial Reports

10-Q Quarterly report [Sections 13 or 15(d)]

2018/06/30

10-K Annual report [Section 13 and 15(d), not S-K Item 405]

2017/12/31

10-Q Quarterly report [Sections 13 or 15(d)]

2017/09/30

10-Q Quarterly report [Sections 13 or 15(d)]

2017/06/30

10-Q Quarterly report [Sections 13 or 15(d)]

2017/03/31

DEF 14A Other definitive proxy statements

2017/05/09

10-K/A Annual report [Section 13 and 15(d), not S-K Item 405]

2016/12/31

4/A Statement of changes in beneficial ownership of securities

2017/02/28

10-K Annual report [Section 13 and 15(d), not S-K Item 405]

2016/12/31

10-Q Quarterly report [Sections 13 or 15(d)]

2016/09/30

Latest Guru Trades with BSX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Select Gurus: | Basic | Premium

| Premium Plus

Guru	Date	Trades	Impact to Portfolio	Price Range * (?)	Current Price	Change from Average	Current Shares
Vanguard Health Care Fund	2018-06-30	Reduce -9.06%	0.21%	$26.84 - $34.32	$ 36.54	21%	35,049,014
David Tepper	2018-06-30	Reduce -35.35%	0.39%	$26.84 - $34.32	$ 36.54	21%	2,528,138
Mario Gabelli	2018-06-30	Reduce -5.84%		$26.84 - $34.32	$ 36.54	21%	312,064
Dodge & Cox	2018-06-30	Reduce -11.08%		$26.84 - $34.32	$ 36.54	21%	211,955
Michael Price	2018-06-30	Reduce -63.06%	0.57%	$26.84 - $34.32	$ 36.54	21%	102,500
Joel Greenblatt	2018-06-30	New Buy	0.03%	$26.84 - $34.32	$ 36.54	21%	59,660
Leucadia National	2018-06-30	New Buy	0.06%	$26.84 - $34.32	$ 36.54	21%	25,000
Vanguard Health Care Fund	2018-03-31	Reduce -3.71%	0.08%	$24.79 - $28.54	$ 36.54	35%	38,541,504
David Tepper	2018-03-31	Reduce -18.23%	0.2%	$24.79 - $28.54	$ 36.54	35%	3,910,738
Mario Gabelli	2018-03-31	Reduce -26.83%	0.02%	$24.79 - $28.54	$ 36.54	35%	331,409
Michael Price	2018-03-31	Reduce -2.36%	0.02%	$24.79 - $28.54	$ 36.54	35%	277,500
Dodge & Cox	2018-03-31	Reduce -5.92%		$24.79 - $28.54	$ 36.54	35%	238,355
Joel Greenblatt	2018-03-31	Sold Out	0.18%	$24.79 - $28.54	$ 36.54	35%	0
Vanguard Health Care Fund	2017-12-31	Add 0.84%	0.02%	$24.79 - $29.8	$ 36.54	32%	40,024,604
David Tepper	2017-12-31	Add 27.44%	0.24%	$24.79 - $29.8	$ 36.54	32%	4,782,683
Joel Greenblatt	2017-12-31	Add 1658.44%	0.17%	$24.79 - $29.8	$ 36.54	32%	503,669
Mario Gabelli	2017-12-31	Reduce -14.20%	0.01%	$24.79 - $29.8	$ 36.54	32%	452,909
Dodge & Cox	2017-12-31	Reduce -16.21%		$24.79 - $29.8	$ 36.54	32%	253,355
Julian Robertson	2017-12-31	Sold Out	5.64%	$24.79 - $29.8	$ 36.54	32%	0

More recent guru trades are included for Premium Members only!!

More recent guru trades are included for USA Subscribe Members only!!

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry:	Medical Devices » Medical Devices NAICS: 339112 SIC: 3841
Compare:	NAS:ISRG, NYSE:EW, NYSE:ZBH, NAS:ALGN, LSE:SN., NYSE:SYK, NAS:ABMD, NYSE:TFX, XSWX:SOON, NYSE:VAR, SZSE:300003, OCSE:WDH, XPAR:DIM, ASX:COH, LSE:CTEC, NZSE:FPH, NYSE:GMED, OCSE:AMBU B, NAS:IART, OCSE:GN » details
Traded in other countries:	BSX.Germany,
Headquarter Location:	USA

Boston Scientific Corp is a developer, manufacturer, and marketer of medical devices. The firm markets its devices to health-care professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.

Boston Scientific produces less-invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract tests, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.

Ratios

		vs industry	vs history
PE Ratio	101.50	BSX's PE Ratio is ranked lower than 98% of the 180 Companies in the Global Medical Devices industry. ( Industry Median: 30.17 vs. BSX: 101.50 ) Ranked among companies with meaningful PE Ratio only. =GURUF("BSX","PE Ratio")	BSX' s PE Ratio Range Over the Past 10 Years Min: 13.87 Med: 57.24 Max: 435 Current: 101.5 13.87 - 435 =GURUF("BSX","PE Ratio")
Forward PE Ratio	23.15	BSX's Forward PE Ratio is ranked higher than 71% of the 52 Companies in the Global Medical Devices industry. ( Industry Median: 25.06 vs. BSX: 23.15 ) Ranked among companies with meaningful Forward PE Ratio only. =GURUF("BSX","Forward PE Ratio")	N/A
PE Ratio without NRI	101.50	BSX's PE Ratio without NRI is ranked lower than 98% of the 179 Companies in the Global Medical Devices industry. ( Industry Median: 30.17 vs. BSX: 101.50 ) Ranked among companies with meaningful PE Ratio without NRI only. =GURUF("BSX","PE Ratio without NRI")	BSX' s PE Ratio without NRI Range Over the Past 10 Years Min: 13.87 Med: 57.24 Max: 435 Current: 101.5 13.87 - 435 =GURUF("BSX","PE Ratio without NRI")
Price-to-Owner-Earnings	61.10	BSX's Price-to-Owner-Earnings is ranked lower than 83% of the 104 Companies in the Global Medical Devices industry. ( Industry Median: 32.03 vs. BSX: 61.10 ) Ranked among companies with meaningful Price-to-Owner-Earnings only. =GURUF("BSX","Price-to-Owner-Earnings")	BSX' s Price-to-Owner-Earnings Range Over the Past 10 Years Min: 11.58 Med: 52.39 Max: 985.26 Current: 61.1 11.58 - 985.26 =GURUF("BSX","Price-to-Owner-Earnings")
PB Ratio	6.52	BSX's PB Ratio is ranked lower than 70% of the 310 Companies in the Global Medical Devices industry. ( Industry Median: 3.06 vs. BSX: 6.52 ) Ranked among companies with meaningful PB Ratio only. =GURUF("BSX","PB Ratio")	BSX' s PB Ratio Range Over the Past 10 Years Min: 0.59 Med: 1.92 Max: 6.87 Current: 6.52 0.59 - 6.87 =GURUF("BSX","PB Ratio")
PS Ratio	5.37	BSX's PS Ratio is ranked lower than 59% of the 294 Companies in the Global Medical Devices industry. ( Industry Median: 3.15 vs. BSX: 5.37 ) Ranked among companies with meaningful PS Ratio only. =GURUF("BSX","PS Ratio")	BSX' s PS Ratio Range Over the Past 10 Years Min: 1.02 Med: 2.23 Max: 5.66 Current: 5.37 1.02 - 5.66 =GURUF("BSX","PS Ratio")
Price-to-Free-Cash-Flow	78.08	BSX's Price-to-Free-Cash-Flow is ranked lower than 61% of the 107 Companies in the Global Medical Devices industry. ( Industry Median: 26.44 vs. BSX: 78.08 ) Ranked among companies with meaningful Price-to-Free-Cash-Flow only. =GURUF("BSX","Price-to-Free-Cash-Flow")	BSX' s Price-to-Free-Cash-Flow Range Over the Past 10 Years Min: 7.21 Med: 22.64 Max: 220 Current: 78.08 7.21 - 220 =GURUF("BSX","Price-to-Free-Cash-Flow")
Price-to-Operating-Cash-Flow	55.03	BSX's Price-to-Operating-Cash-Flow is ranked lower than 66% of the 127 Companies in the Global Medical Devices industry. ( Industry Median: 20.01 vs. BSX: 55.03 ) Ranked among companies with meaningful Price-to-Operating-Cash-Flow only. =GURUF("BSX","Price-to-Operating-Cash-Flow")	BSX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years Min: 5.75 Med: 16.72 Max: 62.72 Current: 55.03 5.75 - 62.72 =GURUF("BSX","Price-to-Operating-Cash-Flow")
EV-to-EBIT	39.51	BSX's EV-to-EBIT is ranked lower than 73% of the 174 Companies in the Global Medical Devices industry. ( Industry Median: 24.76 vs. BSX: 39.51 ) Ranked among companies with meaningful EV-to-EBIT only. =GURUF("BSX","EV-to-EBIT")	BSX' s EV-to-EBIT Range Over the Past 10 Years Min: -5167.6 Med: -3.2 Max: 317.6 Current: 39.51 -5167.6 - 317.6 =GURUF("BSX","EV-to-EBIT")
EV-to-EBITDA	28.32	BSX's EV-to-EBITDA is ranked lower than 69% of the 188 Companies in the Global Medical Devices industry. ( Industry Median: 18.14 vs. BSX: 28.32 ) Ranked among companies with meaningful EV-to-EBITDA only. =GURUF("BSX","EV-to-EBITDA")	BSX' s EV-to-EBITDA Range Over the Past 10 Years Min: -680.1 Med: 11.25 Max: 242.5 Current: 28.32 -680.1 - 242.5 =GURUF("BSX","EV-to-EBITDA")
EV-to-Revenue	5.98	BSX's EV-to-Revenue is ranked lower than 62% of the 309 Companies in the Global Medical Devices industry. ( Industry Median: 3.73 vs. BSX: 5.98 ) Ranked among companies with meaningful EV-to-Revenue only. =GURUF("BSX","EV-to-Revenue")	BSX' s EV-to-Revenue Range Over the Past 10 Years Min: 1 Med: 2.8 Max: 6.3 Current: 5.98 1 - 6.3 =GURUF("BSX","EV-to-Revenue")
Current Ratio	0.83	BSX's Current Ratio is ranked lower than 94% of the 324 Companies in the Global Medical Devices industry. ( Industry Median: 2.71 vs. BSX: 0.83 ) Ranked among companies with meaningful Current Ratio only. =GURUF("BSX","Current Ratio")	BSX' s Current Ratio Range Over the Past 10 Years Min: 0.52 Med: 1.55 Max: 7.77 Current: 0.83 0.52 - 7.77 =GURUF("BSX","Current Ratio")
Quick Ratio	0.60	BSX's Quick Ratio is ranked lower than 93% of the 324 Companies in the Global Medical Devices industry. ( Industry Median: 2.03 vs. BSX: 0.60 ) Ranked among companies with meaningful Quick Ratio only. =GURUF("BSX","Quick Ratio")	BSX' s Quick Ratio Range Over the Past 10 Years Min: 0.33 Med: 1.18 Max: 6.29 Current: 0.6 0.33 - 6.29 =GURUF("BSX","Quick Ratio")
Days Inventory	140.66	BSX's Days Inventory is ranked higher than 50% of the 294 Companies in the Global Medical Devices industry. ( Industry Median: 143.61 vs. BSX: 140.66 ) Ranked among companies with meaningful Days Inventory only. =GURUF("BSX","Days Inventory")	BSX' s Days Inventory Range Over the Past 10 Years Min: 116.64 Med: 135.91 Max: 159.64 Current: 140.66 116.64 - 159.64 =GURUF("BSX","Days Inventory")
Days Sales Outstanding	60.98	BSX's Days Sales Outstanding is ranked higher than 58% of the 276 Companies in the Global Medical Devices industry. ( Industry Median: 69.21 vs. BSX: 60.98 ) Ranked among companies with meaningful Days Sales Outstanding only. =GURUF("BSX","Days Sales Outstanding")	BSX' s Days Sales Outstanding Range Over the Past 10 Years Min: 58.51 Med: 61.98 Max: 66.79 Current: 60.98 58.51 - 66.79 =GURUF("BSX","Days Sales Outstanding")
Days Payable	52.70	BSX's Days Payable is ranked higher than 60% of the 261 Companies in the Global Medical Devices industry. ( Industry Median: 58.34 vs. BSX: 52.70 ) Ranked among companies with meaningful Days Payable only. =GURUF("BSX","Days Payable")	BSX' s Days Payable Range Over the Past 10 Years Min: 24.12 Med: 34.67 Max: 72.7 Current: 52.7 24.12 - 72.7 =GURUF("BSX","Days Payable")

Buy Back

		vs industry	vs history
3-Year Average Share Buyback Ratio	-1.10	BSX's 3-Year Average Share Buyback Ratio is ranked higher than 73% of the 244 Companies in the Global Medical Devices industry. ( Industry Median: -5.70 vs. BSX: -1.10 ) Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only. =GURUF("BSX","3-Year Average Share Buyback Ratio")	BSX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years Min: -25.9 Med: -1 Max: 4.6 Current: -1.1 -25.9 - 4.6 =GURUF("BSX","3-Year Average Share Buyback Ratio")

Valuation & Return

		vs industry	vs history
Price-to-Intrinsic-Value-Projected-FCF	3.82	BSX's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than 64% of the 121 Companies in the Global Medical Devices industry. ( Industry Median: 2.44 vs. BSX: 3.82 ) Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only. =GURUF("BSX","Price-to-Intrinsic-Value-Projected-FCF")	BSX' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years Min: 0.51 Med: 1.62 Max: 500 Current: 3.82 0.51 - 500 =GURUF("BSX","Price-to-Intrinsic-Value-Projected-FCF")
Price-to-Median-PS-Value	2.41	BSX's Price-to-Median-PS-Value is ranked lower than 86% of the 237 Companies in the Global Medical Devices industry. ( Industry Median: 1.02 vs. BSX: 2.41 ) Ranked among companies with meaningful Price-to-Median-PS-Value only. =GURUF("BSX","Price-to-Median-PS-Value")	BSX' s Price-to-Median-PS-Value Range Over the Past 10 Years Min: 0.48 Med: 1.49 Max: 4.29 Current: 2.41 0.48 - 4.29 =GURUF("BSX","Price-to-Median-PS-Value")
Earnings Yield (Greenblatt) %	2.53	BSX's Earnings Yield (Greenblatt) % is ranked higher than 62% of the 332 Companies in the Global Medical Devices industry. ( Industry Median: 0.74 vs. BSX: 2.53 ) Ranked among companies with meaningful Earnings Yield (Greenblatt) % only. =GURUF("BSX","Earnings Yield (Greenblatt) %")	BSX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years Min: -34.3 Med: -0.3 Max: 9.1 Current: 2.53 -34.3 - 9.1 =GURUF("BSX","Earnings Yield (Greenblatt) %")
Forward Rate of Return (Yacktman) %	-15.80	BSX's Forward Rate of Return (Yacktman) % is ranked higher than 96% of the 125 Companies in the Global Medical Devices industry. ( Industry Median: 6.60 vs. BSX: -15.80 ) Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only. =GURUF("BSX","Forward Rate of Return (Yacktman) %")	BSX' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years Min: -11.3 Med: 6.1 Max: 15.4 Current: -15.8 -11.3 - 15.4 =GURUF("BSX","Forward Rate of Return (Yacktman) %")

More Statistics

Revenue (TTM) (Mil) $	9,499.00
EPS (TTM) $	0.36
Beta	1.00
Volatility	21.16%
52-Week Range $	24.54 - 39.44
Shares Outstanding (Mil)	1,382.92

Analyst Estimate

	Dec18	Dec19	Dec20	Dec21
Revenue (Mil $)	9,846	10,541	11,431	12,290
EBIT (Mil $)	1,767	2,180
EBITDA (Mil $)	2,641	3,072
EPS ($)	1.13	1.29	1.36	1.61
EPS without NRI ($)	1.13	1.29	1.36	1.61
EPS Growth Rate (Future 3Y To 5Y Estimate)	40.61%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 7	7
Positive ROA	Y
Positive CFROA	Y
Higher ROA yoy	N
CFROA > ROA	Y
Lower Leverage yoy	Y
Higher Current Ratio yoy	Y
Less Shares Outstanding yoy	N
Higher Gross Margin yoy	Y
Higher Asset Turnover yoy	Y

» More Articles for BSX

Headlines

Articles On GuruFocus.com

Barclays Takes Action on Health Care Stocks Oct 17 2018

Boston Scientific Closes Acquisition of Augmenix, Inc. Oct 16 2018

Steven Cohen Plunges Into Nevro Oct 04 2018

Boston Scientific Announces Conference Call Discussing Third Quarter 2018 Financial Results Oct 01 2018

Align Technology: Hype and Sizzle Sep 27 2018

Boston Scientific Receives U.S. FDA Approval for the Eluvia™ Drug-Eluting Vascular Stent System Sep 24 2018

Boston Scientific Eluvia Drug-Eluting Stent Demonstrates Superior Results In IMPERIAL Trial Sep 22 2018

Boston Scientific Launches LithoVue Empower™ Retrieval Deployment Device Sep 21 2018

Boston Scientific Announces Scheduled Presentations At Transcatheter Cardiovascular Therapeutics 201 Sep 17 2018

Boston Scientific Announces Agreement To Acquire Augmenix, Inc. Sep 06 2018

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

Home About Jobs Advertise Site Map Term of Use Privacy Policy RSS Mobile App Email Alerts Referral Program Affiliate Program FAQ Contact Us
Disclaimers: GuruFocus.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The gurus may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.

Value Screens

Downloads | Tools

Strategies

Market Valuation

By Country

Articles

Submit Articles